Pharmacodynamic Studies on Desogestrel Administered Alone and in Combination with Ethinylestradiol

Acta Obstetricia et Gynecologica Scandinavica

Volumn 64, Issue 133 S, 1985, Pages 1-30

  Cullberg, Göran ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

androgenicity; androgens; body weight; Desogestrel; ethinylestradiol; hirsutism; polycystic ovary syndrome; serum lipids; serum proteins; sex hormone binding globulin

Indexed keywords

EID: 84990498237     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.3109/00016348509157028     Document Type: Article

References (91)

1. Sex‐hormone binding globulin
2. The role of sex hormone binding globulin in health and disease
3. Response of the binding capacity of plasma testosterone‐estradiol‐binding globulin to norethindrone and mestranol 0.1 mg in polycystic ovarian disease
4. Effect of anabolic steroids on hormone‐binding proteins, serum Cortisol and serum nonprotein‐bound Cortisol
5. Effect of body weight reduction on plasma androgens in obese infertile women
6. Ischemic heart disease in women
7. Binding of contraceptive progestogens to receptor proteins in human myometrium and MCF‐7 cells
8. Effect of oestriol, oestradiol valerate and ethinyloestradiol on serum proteins in oestrogen deficient women
9. Effects of oral contraceptive combinations containing levonorgestrel or desogestrel on serum proteins and androgen binding
10. Serum high‐density lipoprotein cholesterol in women using oral contraceptives, estrogens and progestins
11. The beagle dog contraceptive steroids
12. Effect of oral progestogens on estrogen‐induced changes in serum protein
13. A mechanism for the antiandrogenic action of medrogestone
14. Some critical factors in double antibody radioprecipitating sera for measurement of human serum, LH, FSH and HGH
15. Changes in serum apolipoprotein AI and sex‐hormone binding globulin levels after treatment with two different progestins administered alone and in combination with ethinylestradiol
16. R‐New low‐dose, combined, oral contraceptive. Effects on serum proteins, free testosterone and clinical efficacy
17. Desogestrel, a new progestational compound. A comparative study, performed in ovariectomised women
18. Jaundice during treatment with an oral contraceptive, Lyndiol
19. Central and peripheral effects of desogestrel 15–60 μg daily for 21 days in healthy female volunteers
20. Two oral contraceptives, efficacy, serum proteins and lipid metabolism
21. Mood changes and menstrual symptoms with different gestagen/estrogen combinations. A double blind comparison with a placebo
22. Synthesis and release of gonadotropins: Effect of an oral contraceptive
23. The treatment of hirsutism with a combination of desogestrel and ethinyloestradiol
24. Progestational potency of oral contraceptives
25. Relationship of androgenic activity to body fat topography, fat cell morphology and metabolic aberrations in premenopausal women
26. Plasma high‐density lipoprotein cholesterol: Association with measurements of body mass
27. Polycystic ovarian disease
28. Nervousness and depression attributed to oral contraceptives: A double blind, placebo controlled study
29. Studies on the pattern of circulating steroids in the normal menstrual cycle
30. Serum steroid binding protein concentrations, distribution of progestogens and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel
31. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy
32. Investigation of pharmacokinetics of ethinylestradiol to specific consideration of a possible first pass effect in women
33. The Stein‐Leventhal syndrome. Analysis of 43 cases with special reference to association with endometrial carcinoma
34. Depression of the progesterone levels in women treated with synthetic gestagens after ovulation
35. Serum androstenedione and testosterone levels during the menstrual cycle
36. The influence of hormonal contraceptives on sex hormone binding globulin (SHBG) capacity
37. 14C) lynestrenol in man
38. Short‐term effects of desogestrel and ethinylestradiol on serum proteins in women
39. Steroids in ovarian and peripheral venous blood in polycystic ovarian disease
40. Lipoprotein changes may be minimized by proper composition of a combined oral contraceptive
41. Plasma lipids and high density lipoproteins during oral contraceptives with different combinations of ethinylestradiol and levonorgestrel
42. Effect of administration of a combined estrogen‐progestin contraceptive on the level of individual plasma proteins
43. A comparison of plasma protein changes induced by danazol, pregnancy and estrogens
44. Cholesterol, apoproteins, and heart disease. Present status and future prospects
45. Variations in mortality by weight among 750000 men and women
46. Elevations in unbound serum estradiol as a possible mechanism for inappropriate gonadotropin secretion in women with PCO
47. Familial study of hirsutism
48. Sex hormone binding globulin capacity as an index of oestrogenicity or androgenicity in women on oral contraceptive steroids
49. Klinische und biochemische Resultate bei der Behandlung mit Marvelon, einen neuen steroidalen Ovulationshemmer
50. Ethinylestradiol administered by oral and sublingual routes: A comparative study in ovariectomised women
51. The maturation value
52. The origin of androgen synthesis in polycystic ovary syndrome
53. Radioimmunoassay of plasma estrone and estradiol
54. The Tromsö heart study. High‐density lipoprotein and coronary heart disease. A prospective case‐control study
55. Contraceptive mechanism of microdose norethindrone
56. Elevation of certain plasma proteins in man following estrogen administration: A dose‐response relationship
57. In vitro effect of danazol on steroidogenesis in developing human follicles
58. Effects of oestradiol on sex hormone binding globulin
59. Effects on sex hormone binding globulin of different oral contraceptives containing norethisterone and lynestrenol
60. Oral progesterone and estrogen‐progestogen therapy
61. Etude clinique, biologique, anatomique de 6 syndromes de Stein‐Leventhal de l'adolescence
62. Obesity and its role in polycystic ovary syndrome
63. Studies of the relation of plasma androgen levels to androgen action in women
64. Further analyses of mortality in oral contraceptive users
65. The effect of synthetic gestagens on progesterone formation in vitro in human corpus luteum of pregnancy
66. A filter assay for the corticosteroid binding globulin of human serum
67. Efficacy of three phase oral contraceptives. In: International Symposium on Hormonal Contraception. Utrecht 10th Sept 1977
68. The oestrogenic potency of various contraceptive steroids as determined by their effects on transcortin‐binding capacity
69. Normalization of testosterone levels using a low estrogen containing oral contraceptive in women with polycystic ovary syndrome
70. Sex hormone profiles in oligomenorrhoic adolescent girls and the effect of oral contraceptives
71. The influence on the pituitary‐ovarian function, cervical mucus and vaginal cytology of a new progestational compound
72. Sensitivity changes of the pituitary during administration of a triphasic oral contraceptive
73. Amenorrhea associated with bilateral polycystic ovaries
74. 131I‐low density lipoproteins
75. Hormonal consequences of “missing the pill”
76. Capacity of the testosterone‐binding globulin capacity in human plasma and influence of specific binding of testosterone on its metabolic clearance rate
77. Effects of d‐norgestrel induced decreases in sex hormone binding globulin capacity on the d‐norgestrel levels in plasma
78. Sex hormone binding globuline. The carrier protein for d‐norgestrel
79. Free testosterone concentration in serum: A method for determination
80. Radioimmunoassay of a new progestagen, Org 2969 and its metabolite
81. Pharmacological profile of a new orally active progestational steroid, Org 2969
82. High density lipoprotein
83. Evidence for the hypothalamic origin of the polycystic ovary syndrome
84. Abnormalities of fuel metabolism in the polycystic ovary syndrome
85. The polycystic ovary syndrome
86. Cyproterone acetate in the treatment of hirsutism